Statin Therapy: Review of Safety and Potential Side Effects.

Терапия статинами: обзор безопасности и потенциальных побочных эффектов
Satish Ramkumar, Ajay Raghunath, Sudhakshini Raghunath
2016-11-01

cytochrome P450 drug interactionshepatotoxicityrhabdomyolysisstatin therapystatin-related myopathy
BACKGROUND: Hydroxymethyl glutaryl coenzyme A reductase inhibitors, commonly called statins, are some of the most commonly prescribed medications worldwide. Evidence suggests that statin therapy has significant mortality and morbidity benefit for both primary and secondary prevention from cardiovascular disease. Nonetheless, concern has been expressed regarding the adverse effects of long term statin use. The purpose of this article was to review the current medical literature regarding the safety of statins. METHODS: Major trials and review articles on the safety of statins were identified in a search of the MEDLINE database from 1980 to 2016, which was limited to English articles. RESULTS: Myalgia is the most common side effect of statin use, with documented rates from 1-10%. Rhabdomyolysis is the most serious adverse effect from statin use, though it occurs quite rarely (less than 0.1%). The most common risk factors for statin-related myopathy include hypothyroidism, polypharmacy and alcohol abuse. Derangement in liver function tests is common, affecting up to 1% of patients; however, the clinical significance of this is unknown. Some statin drugs are potentially diabetogenic and the risk appears to increase in those patients on higher doses. Pitavastatin has not been associated with increased risk of diabetes. Statins have not been proven to increase the risk of malignancy, dementia, mood disorders or acute interstitial nephritis. However, statins do have multiple drug interactions, primarily those which interact with the cytochrome p450 enzyme group. CONCLUSIONS: Overall, statin drugs appear to be safe for use in the vast majority of patients. However, patients with multiple medical co-morbidities are at increased risk of adverse effects from long-term statin use.
1
Liver function test abnormalities affect up to 1% of patients, although their clinical significance remains uncertain; higher statin doses may increase diabetes risk, whereas pitavastatin has not been associated with increased risk.
2
Myalgia is the most common adverse effect, affecting approximately 1–10% of statin users; hypothyroidism, polypharmacy, and alcohol abuse increase myopathy risk.
3
Patients with multiple medical comorbidities have greater risk of adverse effects during long-term statin therapy.
4
Rhabdomyolysis is the most serious statin-related adverse effect but occurs rarely, in less than 0.1% of users.
5
Statins have not been proven to increase malignancy, dementia, mood disorders, or acute interstitial nephritis, but clinically important interactions occur through cytochrome P450 pathways.
6
Statins provide substantial mortality and morbidity benefits for primary and secondary cardiovascular disease prevention, while appearing safe for most patients.

statin therapy (hydroxymethyl glutaryl coenzyme A reductase inhibitors)

the safety profile and potential adverse effects of long-term statin use, including myopathy, liver-test abnormalities, diabetes risk, and drug interactions

Publication Details
Publication Date
2016-11-01
Journal
Publisher
ISSN
Cited by
358
Access Type
Author Information
Authors
Satish Ramkumar
Ajay Raghunath
Sudhakshini Raghunath
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%